Zhenoluten and Endoluten in women with reduced reproductive function
Comparison in people · 2019
- What was studied
- 276 women aged 34–38: 214 received the peptide combination and 62 received placebo.
- Main finding
- In the 276-person comparison, anti-Müllerian hormone was 1.16 versus 0.82 ng/mL after four months. The expanded report also lists 180/214 versus 8/62 pregnancies, with limited detail on allocation and follow-up.
Anti-Müllerian hormone at month four · 1.16 ± 0.18 ng/mL with the combination versus 0.82 ± 0.24 with placebo. Baselines were 0.76 ± 0.13 and 0.74 ± 0.12 ng/mL, respectively.
Reported findings and study design
From 2013 to 2018, the Moscow center enrolled 276 women aged 34–38. The 214-person combination arm received oral Zhenoluten 20 mg each morning and Endoluten 10 mg every 72 hours for four months. The 62-person comparison received placebo. Neither group received hormone therapy.
Population or model 276 women aged 34–38: 214 received the peptide combination and 62 received placebo.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Anti-Müllerian hormone at month four | 1.16 ± 0.18 ng/mL with the combination versus 0.82 ± 0.24 with placebo. Baselines were 0.76 ± 0.13 and 0.74 ± 0.12 ng/mL, respectively. | |
| Estradiol at month four | 616.24 ± 69.42 pmol/L with the combination versus 209.26 ± 12.64 with placebo. | |
| Pregnancies reported by months four through eight | 180/214 (84%) with the combination versus 8/62 (13%) with placebo. The expanded report supplies no live-birth outcomes or detailed follow-up accounting. |
The authors credit the St. Petersburg Institute of Bioregulation and Gerontology with developing both preparations. The study took place at the Centre for Revitalization and Health in Moscow. The differences come from a comparison with unspecified allocation and masking.
Source for these results ↗ · Reviewed 2026-11-16
Study limitations and source details
Study limitations
- Group assignment and masking are unspecified. The report combines two products, so the effect of either alone is unknown.
- The pregnancy figures come from the authors’ expanded report. Live births, completeness of follow-up and maternal or neonatal safety data are unavailable.
- The conference methods and expanded report agree on every-72-hour Endoluten. A recommendation elsewhere in the conference reproduction gives a different schedule.
Source details
Conference report and expanded author report
Conference reproduction, PDF pages 21–22, and expanded author report, Tables 1–3. Both describe the same participants.
Sources checked
Citation
D. A. Gorgiladze, R. N. Pinaev, V. A. Aleksandrov. Zhenoluten and Endoluten in women with reduced reproductive function 9th European Congress of the International Association of Gerontology and Geriatrics, Gothenburg, 2019. Author material reproduced by Peptides.
Related compounds
Zhenoluten
A peptide mixture described in the Russian report as calf or pig ovary extract. A translated edition gives a conflicting tissue source.
Endoluten
An animal pineal-gland peptide mixture used in the Gazprom occupational research program.